一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）出具的《关于同意南 京麦澜德医疗科技股份有限公司首次公开发行股票注册的批复》 （证监许可〔2022〕 面值为人民币 1 元，每股发行价格为人民币 40.29 元，募集资金总额为人民币 募集资金净额为人民币 90,975.85 万元。天衡会计师事务所（特殊普通合伙）于 2022 年 8 月 8 日对本次发行的资金到位情况进行了审验，并出具了天衡验字(2022)00085 号《验资报告》。 南京证券股份有限公司 关于南京麦澜德医疗科技股份有限公司 使用自筹资金支付募投项目款项 后续以募集资金等额置换的核查意见 南京证券股份有限公司（以下简称"南京证券"或"保荐机构"）作为南京麦澜德 医疗科技股份有限公司（以下简称"麦澜德"或"公司"）首次公开发行股票并在科创 板上市的保荐机构，根据《上市公司募集资金监管规则》《上海证券交易所科创 板股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 等有关规定，对麦澜德使用自筹资金支付募投项目款项后续以募集资金等额置换 事项进行了认真、审慎的核查，核查情况如下： 为规范公司募集资金管 ...

华泰联合证券有限责任公司 关于思瑞浦微电子科技（苏州）股份有限公司 使用募集资金置换预先支付交易现金对价的自筹资金的核 查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"独立财务顾问"） 作为思瑞浦微电子科技（苏州）股份有限公司（以下简称"思瑞浦"、"公司"） 本次发行可转换公司债券及支付现金购买资产并募集配套资金的独立财务顾问， 根据《上市公司募集资金监管规则》 《上海证券交易所科创板股票上市规则》 《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律法规的规定， 对思瑞浦使用募集资金置换预先支付交易现金对价的自筹资金的事项进行审慎 核查，具体核查情况如下： 一、募集资金基本情况 思瑞浦微电子科技（苏州）股份有限公司以发行可转换公司债券及支付现金 的方式购买深圳市创芯微微电子有限公司 100%股权并募集配套资金（以下简称 "本次交易"）。中国证券监督管理委员会出具《关于同意思瑞浦微电子科技（苏 州）股份有限公司发行可转换公司债券购买资产并募集配套资金注册的批复》 （证 监许可〔2024〕1287 号），同意公司发行可转换公司债券及支付现金购买资产并 向特定对象发行股票募集配套资金 ...

西南证券股份有限公司 关于广东松发陶瓷股份有限公司使用募集资金置换 预先投入募投项目的自筹资金的核查意见 西南证券股份有限公司（以下简称"西南证券"或"独立财务顾问"）作为 广东松发陶瓷股份有限公司（以下简称"松发股份"、"上市公司"或"公司"） 的独立财务顾问，根据《上市公司募集资金监管规则》《上海证券交易所上市公 司自律监管指引第 1 号——规范运作》等相关法律法规和规范性文件的规定，对 松发股份使用募集资金置换预先投入募投项目的自筹资金的事项进行了审慎核 查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意广东松发陶瓷股份有限公司发行股 份购买资产并募集配套资金注册的批复》（证监许可〔2025〕1032 号），公司向 特定对象发行人民币普通股（A 股）109,080,992 股，发行价格为人民币 36.67 元 /股，募集资金总额为人民币 3,999,999,976.64 元，扣除各项发行费用人民币 通合伙）审验并出具了中汇会验[2025]10382 号《验资报告》。 为规范公司募集资金的管理和使用，保护投资者的权益，根据中国证监会《上 市公司募集资金监管规则》《上海证券交易所 ...

Group 1 - The board meeting was held on August 20, 2025, with all 7 directors present, and the meeting complied with relevant laws and regulations [1][2] - The board approved the use of raised funds to replace self-raised funds used for project investments and issuance expenses, totaling 264,100 RMB (excluding VAT) [1][2] - The board agreed to use up to 330 million RMB of idle raised funds for cash management, focusing on low-risk, high-liquidity financial products with a maximum investment period of 12 months [2][3] Group 2 - The board approved the temporary use of up to 100 million RMB of idle raised funds to supplement working capital, limited to operations related to the main business, with a maximum usage period of 12 months [3][4] - The board agreed to use self-owned funds and bank acceptance bills to pay for project expenses, with plans to replace these with raised funds later [4][5] - The board unanimously agreed to hold the second temporary shareholders' meeting on September 8, 2025 [5]

证券代码：600930 证券简称：华电新能 公告编号：2025-006 华电新能源集团股份有限公司 公司监事会认为：公司本次使用行使超额配售选择权对应的募集资金置换预先投入募投项目的自筹资 金，提高了募集资金使用效率，符合全体股东利益。上述事项内容及审议程序符合《上海证券交易所股 票上市规则》《上海证券交易所上市公司自律监管指引第1号一一规范运作》等相关法律法规的有关规 定，不影响募集资金投资项目的正常进行，不存在变相改变募集资金用途和损害股东利益的情形。公司 监事会同意公司使用行使超额配售选择权对应的募集资金235,252.84万元置换预先投入募投项目的自筹 资金。 表决情况：3票同意、0票反对、0票弃权。 特此公告。 一、 监事会会议召开情况 2025年8月18日，华电新能源集团股份有限公司（以下简称"公司"）第一届监事会第十二次会议以通讯 方式举行。本次会议通知于2025年8月15日以通讯方式向全体监事发出。本次会议应出席监事3名，亲自 出席监事3名，会议由邵福生主席主持。本次会议的召开符合《公司法》《公司章程》等法规及规范性 文件的有关规定。 二、监事会会议审议情况 本次会议经与会监事充分审议并有效表 ...

中信建投证券股份有限公司 关于安徽芯动联科微系统股份有限公司 使用自有资金支付募投项目所需资金并以募集资金等额置换的 核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"、"保荐人"）为 安徽芯动联科微系统股份有限公司（以下简称"芯动联科"、"公司"）首次 公开发行股票并在科创板上市的保荐人及持续督导机构，根据《证券发行上市保 荐业务管理办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票 上市规则》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》 等法规的有关规定，对芯动联科使用自有资金支付募投项目所需资金并以募集资金 等额置换事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意安徽芯动联科微系统股份有 限公司首次公开发行股票注册的批复》（证监许可[2023]1012号）同意，安徽 芯动联科微系统股份有限公司（以下简称"公司"）首次向社会公开发行人民 币普通股（A股）5,521万股。公司每股发行价格26.74元，新股发行募集资金总 额为147,631.54万元，扣除发行费用12,195.64万元后，募集资金净额135,435.90 ...

Core Viewpoint - The company, Shanghai Hehui Optoelectronics Co., Ltd., is utilizing its own funds to pay for part of the fundraising investment projects and will subsequently replace these with equivalent amounts from the raised funds, ensuring compliance with relevant regulations and maintaining operational efficiency [1][6]. Summary of Fundraising Situation - The company was approved to publicly issue shares, with a total of 3,083,660,725 shares issued at a price of 2.65 RMB per share, resulting in a net fundraising amount of approximately 8 billion RMB [1]. - As of June 30, 2025, the total committed investment for the sixth-generation AMOLED production line expansion project is approximately 800 million RMB, with cumulative investment amounting to about 663 million RMB [2]. Fundraising Investment Project Process - The company will initially use its own funds to pay for overseas equipment and services due to restrictions on the fundraising account, and will later replace these with raised funds [2][4]. - The finance department will track payments made with its own funds and will compile monthly summaries to ensure compliance with the company's fundraising management regulations [2][4]. Impact on Daily Operations - The approach of using own funds for project payments is expected to enhance fund utilization efficiency and will not affect the normal operation of fundraising investment projects or harm the interests of the company and its shareholders [4]. Decision-Making Procedures - The company’s board and supervisory committee approved the use of own funds for project payments and subsequent replacement with raised funds, ensuring compliance with legal and regulatory requirements [5]. Supervisory Committee Opinion - The supervisory committee agrees that the use of own funds followed by replacement with raised funds aligns with relevant regulations and does not alter the purpose of the raised funds or harm shareholder interests [5][6]. Sponsor Institution's Verification Opinion - The sponsor institution confirms that the company has followed necessary procedures and that the use of own funds for project payments will not disrupt the normal progress of fundraising investment projects [6].

Meeting Overview - The third meeting of the board of directors of Jiangsu Aidi Pharmaceutical Group Co., Ltd. was held on August 14, 2025, with all 7 directors present, complying with relevant regulations [1]. Agenda Items - The board approved the adjustment of the 2025 stock option incentive plan, reducing the number of incentive recipients from 45 to 43 and the total stock options from 9.1 million to 8.96 million due to the departure of 2 recipients [1][2]. - The board agreed to grant stock options to the 2025 incentive recipients, with the grant date set for August 14, 2025, and a total of 8.96 million stock options to be issued at an exercise price of 13.01 yuan per share [2][3]. - The board approved the use of self-owned funds and bank acceptance bills to finance fundraising projects, which will be replaced by the raised funds, enhancing fund efficiency and reducing costs [3][4].

Core Viewpoint - Zhejiang Meilun Elevator Co., Ltd. has made significant decisions regarding the use of raised funds, including replacing self-raised funds and managing idle funds, which are expected to enhance financial efficiency and shareholder returns [2][3][5][7]. Fund Management - The company plans to use raised funds to replace self-raised funds amounting to RMB 75.27 million and issuance expenses of RMB 1.86 million, totaling RMB 77.13 million [2][3][6]. - The replacement of funds will occur within six months of the funds being received [3][6]. - The company intends to manage idle raised funds of up to RMB 150 million for cash management, ensuring it does not affect the normal investment plans [7][8]. Capital Changes - The company has approved a change in registered capital from RMB 307 million to RMB 349.05 million following a stock issuance of 42,049,469 shares at a price of RMB 5.66 per share [4][6]. - The updated capital structure will be reflected in the company's articles of association, which will be revised accordingly [4][6]. Financial Performance - As of August 5, 2025, Meilun Elevator's stock closed at RMB 9.01, marking a 3.8% increase with a trading volume of 139,100 lots and a turnover of RMB 123 million [1][2]. - The net inflow of main funds on that day was RMB 16.31 million, accounting for 13.27% of the total turnover [2][5].

Core Viewpoint - The company intends to use its own funds to pay for part of the investment project and subsequently replace it with raised funds, which is in compliance with regulatory requirements and aims to enhance the efficiency of fund utilization [1][5]. Fundraising Basic Situation - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds, with net fundraising amounting to approximately 253.43 million yuan after deducting related expenses [1][2]. Investment Project Basic Situation - As of June 30, 2025, the total investment for the projects, including the Jiangsu Phase II, Hubei Pharmaceutical Sorting and Processing Center, and Hebei Pharmaceutical Warehouse, amounts to 253.43 million yuan, with 179.74 million yuan allocated from the raised funds [2]. Reasons for Using Own Funds - The company faces challenges in using raised funds directly for certain expenses, such as employee salaries and social insurance, which must be paid through the basic deposit account. Therefore, it plans to use up to 7.05 million yuan of its own funds for these payments and later replace them with raised funds [3][4]. Impact on the Company - The use of self-funds for project payments and subsequent replacement with raised funds is expected to improve fund utilization efficiency and ensure the smooth progress of investment projects without affecting the normal implementation of the projects [4][5]. Review Procedures and Opinions - The company's board and supervisory committee have approved the proposal to use self-funds for the investment project, confirming that this action does not harm the interests of the company or its shareholders and complies with relevant regulations [5].